Research progress of immune checkpoint inhibitors associated pneumonia

WANG Jie; JIANG Shiqing; WANG Tao

doi:10.7619/jcmp.20220546

Journal of Clinical Medicine in Practice > 2022 > 26(10): 135-138, 143. > DOI: 10.7619/jcmp.20220546

WANG Jie, JIANG Shiqing, WANG Tao. Research progress of immune checkpoint inhibitors associated pneumonia[J]. Journal of Clinical Medicine in Practice, 2022, 26(10): 135-138, 143. DOI: 10.7619/jcmp.20220546

Citation:

PDF (659 KB)

Research progress of immune checkpoint inhibitors associated pneumonia

WANG Jie¹,
JIANG Shiqing^{1, 2, ,},
WANG Tao²

1.
Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, 450003
2.
Department of Hematology and Oncology, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, 450099

More Information

Received Date: February 21, 2022
Available Online: May 04, 2022

Graphical Abstract

Abstract

Abstract

Immune checkpoint inhibitors (ICIS) are widely used in the treatment of a variety of malignant tumors, but the over activation of the immune system induced by ICIS will also lead to T cells attacking their own antigens, and cause a series of immune related adverse events (IRAEs) in clinic. Immune checkpoint inhibitor associated pneumonia (CIP) is a rare but potentially fatal immune related adverse reaction that occurs at any time of tumor immunotherapy. Clinicians should understand the mechanism and characteristics of CIP, and identify and deal with it correctly as soon as possible. This paper reviewed the epidemiology, biological mechanism, clinical characteristics, diagnosis and treatment of CIP.
- immune checkpoint inhibitors,
- immune system,
- immune checkpoint inhibitor associated pneumonia,
- epidemiology,
- biological mechanism

FullText(HTML)

References (40)

References

[1]	ALSAAB H O, SAU S, ALZHRANI R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome[J]. Front Pharmacol, 2017, 8: 561. doi: 10.3389/fphar.2017.00561
[2]	崔建东, 张羽, 王红治. 免疫检查点抑制剂在非小细胞肺癌治疗中的临床应用[J]. 肿瘤药学, 2019, 9(1): 14-19. doi: 10.3969/j.issn.2095-1264.2019.01.04
[3]	FRIEDMAN C F, PROVERBS-SINGH T A, POSTOW M A. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review[J]. JAMA Oncol, 2016, 2(10): 1346-1353. doi: 10.1001/jamaoncol.2016.1051
[4]	POZZESSERE C, BOUCHAAB H, JUMEAU R, et al. Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study[J]. ERJ Open Res, 2020, 6(1): 00165-02019.
[5]	SURESH K, NAIDOO J, LIN C T, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities[J]. Chest, 2018, 154(6): 1416-1423. doi: 10.1016/j.chest.2018.08.1048
[6]	BOUTROS C, TARHINI A, ROUTIER E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J]. Nat Rev Clin Oncol, 2016, 13(8): 473-486. doi: 10.1038/nrclinonc.2016.58
[7]	BAXI S, YANG A N, GENNARELLI R L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis[J]. BMJ, 2018, 360: k793.
[8]	WANG D Y, SALEM J E, COHEN J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. doi: 10.1001/jamaoncol.2018.3923
[9]	NISHINO M, RAMAIYA N H, AWAD M M, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course[J]. Clin Cancer Res, 2016, 22(24): 6051-6060. doi: 10.1158/1078-0432.CCR-16-1320
[10]	NISHINO M, HATABU H. Programmed death-1/programmed death ligand-1 inhibitor-related pneumonitis and radiographic patterns[J]. J Clin Oncol, 2017, 35(14): 1628-1629.
[11]	NISHINO M, GIOBBIE-HURDER A, HATABU H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2016, 2(12): 1607-1616. doi: 10.1001/jamaoncol.2016.2453
[12]	HODI F S, O'DAY S J, MCDERMOTT D F, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8): 711-723. doi: 10.1056/NEJMoa1003466
[13]	WOLCHOK J D, NEYNS B, LINETTE G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study[J]. Lancet Oncol, 2010, 11(2): 155-164. doi: 10.1016/S1470-2045(09)70334-1
[14]	KUMAR V, CHAUDHARY N, GARG M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy[J]. Front Pharmacol, 2017, 8: 49. doi: 10.3389/fphar.2017.00049
[15]	ATCHLEY W T, ALVAREZ C, SAXENA-BEEM S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer[J]. Chest, 2021, 160(2): 731-742. doi: 10.1016/j.chest.2021.02.032
[16]	SURESH K, VOONG K R, SHANKAR B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors[J]. J Thorac Oncol, 2018, 13(12): 1930-1939. doi: 10.1016/j.jtho.2018.08.2035
[17]	TONE M, IZUMO T, AWANO N, et al. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer[J]. Thorac Cancer, 2019, 10(10): 2006-2012. doi: 10.1111/1759-7714.13187
[18]	CHO J Y, KIM J, LEE J S, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer[J]. Lung Cancer, 2018, 125: 150-156. doi: 10.1016/j.lungcan.2018.09.015
[19]	NISHINO M, HATABU H, HODI F S, et al. Drug-related pneumonitis in the era of precision cancer therapy[J]. JCO Precis Oncol, 2017, 1: PO. 17. 00026.
[20]	SHOHDY K S, ABDEL-RAHMAN O. Risk of pneumonitis with different immune checkpoint inhibitors in NSCLC[J]. Ann Transl Med, 2017, 5(17): 365. doi: 10.21037/atm.2017.06.67
[21]	FUJⅡ T, COLEN R R, BILEN M A, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience[J]. Investig New Drugs, 2018, 36(4): 638-646. doi: 10.1007/s10637-017-0534-0
[22]	POSTOW M A, SIDLOW R, HELLMANN M D. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. doi: 10.1056/NEJMra1703481
[23]	TABCHI S, MESSIER C, BLAIS N. Immune-mediated respiratory adverse events of checkpoint inhibitors[J]. Curr Opin Oncol, 2016, 28(4): 269-277. doi: 10.1097/CCO.0000000000000291
[24]	LATCHMAN Y, WOOD C R, CHERNOVA T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol, 2001, 2(3): 261-268. doi: 10.1038/85330
[25]	CHUZI S, TAVORA F, CRUZ M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis[J]. Cancer Manag Res, 2017, 9: 207-213. doi: 10.2147/CMAR.S136818
[26]	HASSEL J C, HEINZERLING L, ABERLE J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions[J]. Cancer Treat Rev, 2017, 57: 36-49. doi: 10.1016/j.ctrv.2017.05.003
[27]	NAIDOO J, WANG X, WOO K M, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7): 709-717. doi: 10.1200/JCO.2016.68.2005
[28]	王汉萍, 郭潇潇, 周佳鑫, 等. 免疫检查点抑制剂相关肺炎的临床诊治建议[J]. 中国肺癌杂志, 2019, 22(10): 621-626. doi: 10.3779/j.issn.1009-3419.2019.10.03
[29]	WIDMANN G, NGUYEN V A, PLAICKNER J, et al. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy[J]. Curr Radiol Rep, 2016, 5(11): 59.
[30]	DELAUNAY M, CADRANEL J, LUSQUE A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients[J]. Eur Respir J, 2017, 50(2): 1700050. doi: 10.1183/13993003.00050-2017
[31]	SUZUKI K, YANAGIHARA T, MATSUMOTO K, et al. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease[J]. Int Immunol, 2020, 32(8): 547-557. doi: 10.1093/intimm/dxaa022
[32]	NAKASHIMA K, NAITO T, OMORI S, et al. Organizing pneumonia induced by nivolumab in a patient with metastatic melanoma[J]. J Thorac Oncol, 2016, 11(3): 432-433. doi: 10.1016/j.jtho.2015.10.004
[33]	ISHIWATA T, EBATA T, IWASAWA S, et al. Nivolumab-induced acute fibrinous and organizing pneumonia (AFOP)[J]. Intern Med, 2017, 56(17): 2311-2315. doi: 10.2169/internalmedicine.8271-16
[34]	BARJAKTAREVIC I Z, QADIR N, SURI A N, et al. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma[J]. Chest, 2013, 143(3): 858-861. doi: 10.1378/chest.12-1467
[35]	MATSUKANE R, WATANABE H, MINAMI H, et al. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events[J]. Sci Rep, 2021, 11(1): 1324. doi: 10.1038/s41598-020-79397-6
[36]	王锋, 秦叔逵, 华海清, 等. 免疫检查点抑制剂相关性肺炎的临床特点及分型研究[J]. 临床肿瘤学杂志, 2021, 26(6): 541-549. doi: 10.3969/j.issn.1009-0460.2021.06.011
[37]	ZHAI X Y, ZHANG J, TIAN Y R, et al. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients[J]. Cancer Biol Med, 2020, 17(3): 599-611. doi: 10.20892/j.issn.2095-3941.2020.0102
[38]	KALISZ K R, RAMAIYA N H, LAUKAMP K R, et al. Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management[J]. Radiographics, 2019, 39(7): 1923-1937. doi: 10.1148/rg.2019190036
[39]	张勇. 肿瘤免疫检查点抑制剂相关肺炎的管理[J]. 中国临床医学, 2020, 27(6): 922-925. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX202006006.htm
[40]	THOMPSON J A. New NCCN guidelines: recognition and management of immunotherapy-related toxicity[J]. J Natl Compr Canc Netw, 2018, 16(5S): 594-596. doi: 10.6004/jnccn.2018.0047

[1]	ZHANG Wensen, WANG Zhendong, FU Ying, MA Guoda, CHEN Riling. Research trend and hotspots in cardiovascular immune-related adverse events induced by immune checkpoint inhibitor therapy: a CiteSpace based visual analysis[J]. Journal of Clinical Medicine in Practice, 2025, 29(5): 1-8, 15. DOI: 10.7619/jcmp.20245262
[2]	ZHANG Aiping, CHEN Jue. Progress in the pathogenesis, clinical diagnosis and treatment of immune checkpoint inhibitor-related pneumonitis[J]. Journal of Clinical Medicine in Practice, 2024, 28(6): 133-138. DOI: 10.7619/jcmp.20232951
[3]	SUN Liyi, HE Xiaofang, JIANG Yuanhui, HUA Xiaofan, ZHOU Min. Relationships of ultrasound vascular index quantification and elastic modulus with biological characteristics of breast cancer and its clinical significance[J]. Journal of Clinical Medicine in Practice, 2024, 28(4): 115-119. DOI: 10.7619/jcmp.20233893
[4]	YIN Jia, WANG Di, HUANG Cheng. An epidemiological study of Norovirus in patients with acute gastroenteritis in primary and secondary schools as well as childcare facilities[J]. Journal of Clinical Medicine in Practice, 2023, 27(19): 75-79. DOI: 10.7619/jcmp.20232191
[5]	ZHENG Lingling, MENG Yinmei, LIU Nannan, YE Xiaoxin, MA Junjun, LI Ming, LI Wei. Epidemiological characteristics of viral hepatitis C in Fuyang city and influencing factors of disease progression[J]. Journal of Clinical Medicine in Practice, 2022, 26(12): 61-64. DOI: 10.7619/jcmp.20220355
[6]	XIONG Mei, LUO Zhicheng. Research progress on epidemiology of herpes zoster[J]. Journal of Clinical Medicine in Practice, 2022, 26(7): 144-148. DOI: 10.7619/jcmp.20214502
[7]	CAO Yu, FANG Fang. Study on adjuvant chemotherapy of luminal A type breast cancer based on Surveillance, Epidemiology and End Results Database[J]. Journal of Clinical Medicine in Practice, 2021, 25(6): 4-7, 12. DOI: 10.7619/jcmp.20201026
[8]	ZHANG Peng. Advances of computational biology and the shortage of its talents[J]. Journal of Clinical Medicine in Practice, 2020, 24(1): 7-9. DOI: 10.7619/jcmp.202001002
[9]	ZHANG Qingjuan, ZHU Jiang, GONG Yuxiang. Epidemiological characteristics and relationship between pathological types and immunofluorescence of 508 renal biopsy materials[J]. Journal of Clinical Medicine in Practice, 2012, (23): 59-61.
[10]	HU Jian, YANG Jun, JIANG Ying-hong, LIU Pin, LIAO Ze. EPIDEMIOLOGIC INVESTIGATION ON HYPERTENSION AND ITS RELATED DISEASES AMONG 1 402 MIDDLE SCHOOL TEACHERS IN GUIYANG[J]. Journal of Clinical Medicine in Practice, 2005, (3): 73-75. DOI: 10.3969/j.issn.1672-2353.2005.03.025

Cited By

Cited by

Periodical cited type(4)

1.	刘佳，王坚，顾小伟，蔡依玲，何佳，孙玲娣，于波，舒忠琴，沙莎. 大分割放疗联合免疫检查点抑制剂治疗晚期转移性实体瘤的临床疗效研究. 实用临床医药杂志. 2024(06): 19-23 . 本站查看
2.	张爱萍，陈珏. 免疫检查点抑制剂相关肺炎的发病机制及临床诊治进展. 实用临床医药杂志. 2024(06): 133-138 . 本站查看
3.	刘家骏，刘国康，朱玉虎. 免疫相关性重症肺炎1例. 北京大学学报(医学版). 2024(05): 932-937 .
4.	马超，向兰，杨青斌，李进，徐静. 替雷利珠单抗致免疫性肺炎1例. 中国医药科学. 2022(22): 182-185 .

Other cited types(1)

Get Citation

PDF

XML

Article views (527) PDF downloads (98) Cited by(5)

Turn off MathJax

Article Contents

Abstract

References

Research progress of immune checkpoint inhibitors associated pneumonia

Abstract

References

Related Articles

Cited by

Periodical cited type(4)

Other cited types(1)

Catalog

Research progress of immune checkpoint inhibitors associated pneumonia

Abstract

References

Related Articles

Cited by

Periodical cited type(4)

Other cited types(1)

Catalog

Export File

Citation

Format

Content